Last reviewed · How we verify
NCT03872440
PDX Models From EGFR Mutant Tumors
trial in Non Small Cell Lung Cancer. Withdrawn.
6 January 2020
Quick facts
| Lead sponsor | Addario Lung Cancer Medical Institute |
|---|---|
| Status | Withdrawn |
| Study type | OBSERVATIONAL |
| Start date | 14 November 2018 |
| Primary completion | 6 January 2020 |
| Estimated completion | 6 January 2020 |
| Sites | 1 location across United States |
Conditions studied
- Non Small Cell Lung Cancer — all drugs for Non Small Cell Lung Cancer →
Sponsor
Addario Lung Cancer Medical Institute
Who can join
18 and older, any sex, with Non Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A biospecimen collection study from individuals with EGFR mutant cancers resistant to EGFR TKIs or those harboring an Exon 20 insertion mutation.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Harnessing PDX and PDX 2.0: the next-generation paradigm for precision oncology and translational breakthroughs.
Jian C, Fu H, Wu W, Zhang N, et al · · 2026 · PMID 41699647 · DOI 10.1186/s12943-026-02594-w
Verify or expand the search:
- PubMed search for NCT03872440
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Non Small Cell Lung Cancer
Currently open trials in the same condition.
- NCT06951646 — ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immuno · Phase 2 · recruiting
- NCT07503808 — A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types · Phase 1 · recruiting
- NCT07269782 — A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCL · Phase 2 · recruiting
- NCT07306624 — Nelmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer · Phase 2 · recruiting
- NCT07323732 — A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Diseas · Phase 2 · recruiting
Other Addario Lung Cancer Medical Institute trials
Trials by the same sponsor.
- NCT04676386 — Biomarker Analysis in High PD-L1 Expressing NSCLC Patients Treated With PD-1/PD-L1 Based Therapy With or Without the Add · terminated
- NCT03833934 — Study of Plasma NGS for Assessment, Characterization, Evaluation of Patients With ALK Resistance · completed
- NCT03553550 — Role of Circulating Tumor DNA (ctDNA) From LIquid Biopsy in Early Stage NSCLC Resected Lung Tumor Investigation · terminated
- NCT03497624 — ALCMI-006: A Prospective Biospecimen Collection Study From Patients With ROS1-Fusion Positive Tumors · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03872440 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Addario Lung Cancer Medical Institute
- Last refreshed: 9 January 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03872440.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing